Boehringer Ingelheim Introduces VETMEDIN® Solution, a Liquid Treatment for Canine Heart Failure

Boehringer Ingelheim Introduces VETMEDIN® Solution, a Liquid Treatment for Canine Heart Failure

(IN BRIEF) Boehringer Ingelheim has launched VETMEDIN® Solution, the first FDA-approved liquid treatment for congestive heart failure (CHF) in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). The solution provides a convenient, twice-daily alternative to tablets, ideal for smaller dogs or those who prefer liquid medication. Backed by clinical studies, VETMEDIN® improves survival times and quality of life for dogs with CHF. This launch adds to Boehringer Ingelheim’s legacy of advancing animal health, with VETMEDIN® already helping dogs enjoy over 1 million additional years of life.

(PRESS RELEASE) INGELHEIM, 27-Nov-2024 — /EuropaWire/ — Boehringer Ingelheim, a global leader in animal health, has launched VETMEDIN® Solution, the first FDA-approved oral liquid solution for managing congestive heart failure (CHF) in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). Heart disease affects approximately 10% of dogs during their lifetime, with MMVD and DCM being the most common causes of CHF.

This new liquid formulation provides pet owners with a convenient alternative to VETMEDIN® Chewable Tablets, offering the same dual mode of action to support heart health in dogs. The flavorless solution is administered twice daily directly into a dog’s mouth, making it an ideal option for smaller dogs or those who struggle with tablets.

Backed by Clinical Evidence

Studies have demonstrated that VETMEDIN® significantly improves survival times and quality of life for dogs suffering from CHF due to MMVD or DCM. “We are committed to delivering innovations that help pets live longer, healthier lives,” said Daniel Watkins, Vice President of Boehringer Ingelheim’s US Pet Business. “VETMEDIN® Solution gives pet owners another way to manage their dog’s heart disease effectively.”

A Legacy of Heart Health Support

For 25 years, VETMEDIN® has been a cornerstone of canine cardiology, helping dogs and their families enjoy more than 1 million additional years of life together. Boehringer Ingelheim also offers VETMEDIN®-CA1 (pimobendan), conditionally approved by the FDA for Stage B2 preclinical MMVD, which may delay the onset of heart failure symptoms.

The launch of VETMEDIN® Solution marks another milestone in Boehringer Ingelheim’s mission to advance animal health through innovative, evidence-based treatments. For more information, visit www.boehringer-ingelheim.com/animal-health.

Boehringer Ingelheim – Animal Health business

Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at https://www.boehringer-ingelheim.com/animal-health.

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com/.

Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

References 

1  Keene, Bruce W et al. “ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.” Journal of Veterinary Internal Medicine vol. 33,3 (2019): 1127-1140. doi:10.1111/jvim.15488

2 Häggström, J et al. “Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.” Journal of Veterinary Internal Medicine vol. 27,6 (2013): 1441-51. doi:10.1111/jvim.12181

3 Lombard, Christophe W et al. “Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.” Journal of the American Animal Hospital Association vol. 42,4 (2006): 249-61. doi:10.5326/0420249

4 Epidemiologic simulation of Vetmedin usage 1999-2024, based on EPIC 2016 JVIM (MMVD, stage B2), QUEST 2008 JVIM (MMVD, stage C), PROTECT 2012 JVIM (DCM, stage B2), O`Grady 2008 JVIM (DCM, stage C), Fuentes 2002 JVIM (DCM stage C) and BI-owned sales data.

Media Contact:

Mi-Kyung Lee-Lange
Animal Health Communications Lead
email: mi-kyung.lee-lange@boehringer-ingelheim.com

SOURCE: Boehringer Ingelheim